ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) – Research analysts at SVB Leerink increased their Q2 2022 earnings estimates for ShockWave Medical in a research report issued to clients and investors on Monday, May 9th. SVB Leerink analyst D. Antalffy now anticipates that the company will post earnings of $0.41 per share for the quarter, up from their prior estimate of $0.30. SVB Leerink currently has a “Outperform” rating and a $190.00 price target on the stock. SVB Leerink also issued estimates for ShockWave Medical’s FY2022 earnings at $1.89 EPS, Q1 2023 earnings at $0.57 EPS, Q2 2023 earnings at $0.63 EPS, Q3 2023 earnings at $0.66 EPS, Q4 2023 earnings at $0.75 EPS and FY2025 earnings at $5.45 EPS.
ShockWave Medical (NASDAQ:SWAV – Get Rating) last announced its earnings results on Monday, May 9th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.20. ShockWave Medical had a negative return on equity of 4.18% and a negative net margin of 3.85%. The business had revenue of $93.70 million during the quarter, compared to analyst estimates of $86.41 million. During the same quarter in the previous year, the business earned ($0.68) earnings per share. The company’s revenue for the quarter was up 193.7% compared to the same quarter last year.
Shares of NASDAQ:SWAV opened at $136.14 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.54 and a quick ratio of 4.71. The firm has a market capitalization of $4.87 billion, a PE ratio of -453.80 and a beta of 1.50. The business has a 50 day simple moving average of $180.52 and a two-hundred day simple moving average of $179.24. ShockWave Medical has a 1 year low of $113.36 and a 1 year high of $249.73.
In related news, insider Isaac Zacharias sold 4,000 shares of the company’s stock in a transaction on Tuesday, February 15th. The stock was sold at an average price of $149.96, for a total value of $599,840.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Trinh Phung sold 3,176 shares of the company’s stock in a transaction on Tuesday, April 12th. The shares were sold at an average price of $215.61, for a total value of $684,777.36. Following the completion of the transaction, the vice president now directly owns 29,695 shares in the company, valued at $6,402,538.95. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 99,242 shares of company stock worth $16,799,585. Insiders own 15.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of ShockWave Medical by 5.5% in the 4th quarter. BlackRock Inc. now owns 2,716,533 shares of the company’s stock valued at $484,441,000 after acquiring an additional 142,368 shares during the period. Invesco Ltd. increased its position in shares of ShockWave Medical by 116.1% in the 3rd quarter. Invesco Ltd. now owns 1,310,949 shares of the company’s stock valued at $269,897,000 after acquiring an additional 704,446 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of ShockWave Medical in the 4th quarter valued at $168,314,000. State Street Corp boosted its holdings in ShockWave Medical by 2.0% in the fourth quarter. State Street Corp now owns 701,375 shares of the company’s stock valued at $125,076,000 after purchasing an additional 13,712 shares during the last quarter. Finally, Credit Suisse AG boosted its holdings in ShockWave Medical by 14.7% in the fourth quarter. Credit Suisse AG now owns 689,659 shares of the company’s stock valued at $122,987,000 after purchasing an additional 88,622 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
ShockWave Medical Company Profile (Get Rating)
ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.
- Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
- Fifth Third Bancorp Stock Bestows Opportunity
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.